Chemical-Guided SHAPE Sequencing Defines Antiviral Chimera Binding in SARS-CoV-2 5’ UTR

Study Background and Research Question

Structured RNA elements within viral genomes, especially untranslated regions (UTRs), play essential roles in replication, translation, and packaging, making them attractive antiviral targets. In SARS-CoV-2, the 5’ UTR is highly conserved and contains defined stem-loop structures (SL1–SL5) critical for viral lifecycle processes such as ribosome recruitment and subgenomic RNA synthesis (reference). The ability to accurately map where small molecules or chimeric degraders bind on these structured RNAs is paramount for advancing RNA-targeted antiviral strategies. However, conventional techniques often lack the resolution or throughput to unambiguously identify such binding sites at single-nucleotide precision in complex RNA structures.

Key Innovation from the Reference Study

The study by Tang et al. introduces chemical-guided SHAPE sequencing (cgSHAPE-seq), a novel approach that adapts the principles of selective 2′-hydroxyl acylation analyzed by primer extension (SHAPE) to pinpoint the binding sites of reactive small molecules on structured viral RNA (reference). Unlike traditional SHAPE, cgSHAPE-seq deploys acylating probes tethered to the ligand of interest, enabling site-specific crosslinking at the point of molecular interaction. This innovation allows researchers to observe mutation signatures during reverse transcription, directly correlating with the site of acylation and, by extension, ligand binding.

Methods and Experimental Design Insights

The cgSHAPE-seq workflow begins with the synthesis of coumarin-based chemical probes able to acylate 2’-OH groups of ribose residues upon binding to their RNA targets. The study focused on SL5, a four-way junction in the SARS-CoV-2 5’ UTR, screening a library of coumarin derivatives to identify potent binders (notably, C30 and C34). These probes were incubated with in vitro transcribed SL5 RNA, allowing the acylation reaction to occur specifically at the ligand binding site. Subsequent reverse transcription (primer extension) steps introduce mutation signatures at the modified positions, which are then identified via next-generation sequencing. This enables single-nucleotide resolution mapping of small molecule–RNA interactions. The authors then designed chimeric molecules by replacing the acylating group in the cgSHAPE probe with a ribonuclease L recruiter (RLR) moiety, creating bifunctional degraders. These chimeras aim to target viral RNA for degradation either in vitro or in cellular models expressing the SARS-CoV-2 5’ UTR.

Protocol Parameters

• cgSHAPE-seq assay | 1–5 μM probe | Mapping RNA-ligand binding sites | Ensures sufficient probe for single-nucleotide mapping | paper
• In vitro transcription RNA protection | 0.5–1 U/μL Murine RNase Inhibitor | Prevents RNase-mediated degradation during transcript synthesis | Maintains RNA integrity for downstream mapping | workflow_recommendation
• Reverse transcription (primer extension) | 1–10 ng/μL RNA | Detects mutation signatures from acylated nucleotides | Balances template input for accurate sequencing | paper
• RLR chimera in vitro degradation assay | 10–100 nM chimera | Tests RNA-degrader activity | Evaluates dose-dependent RNA cleavage | paper

Core Findings and Why They Matter

cgSHAPE-seq successfully mapped the primary binding site of the coumarin derivative C30 to a bulged guanine in SL5 of the SARS-CoV-2 5’ UTR. This assignment was validated by site-directed mutagenesis and binding assays, confirming the specificity of the ligand–RNA interaction (reference). The study further demonstrated that RLR-chimera variants, guided by this mapping, could trigger RNase L–mediated cleavage of the viral 5’ UTR both in vitro and in cell-based systems. Notably, optimized chimeras such as C64 achieved robust inhibition of live SARS-CoV-2 replication in lung epithelial carcinoma cells, establishing proof-of-principle for targeted viral RNA degradation. These findings highlight the utility of cgSHAPE-seq in guiding the design and mechanistic validation of RNA-degrading therapeutics. The method provides a generalizable platform for mapping ligand–RNA interactions, which is crucial for precision antiviral strategies targeting highly structured and conserved RNA elements.

Comparison with Existing Internal Articles

Several internal resources discuss the importance of robust RNA degradation prevention and the role of oxidation-resistant RNase inhibitors in maintaining RNA integrity during molecular workflows:

• Murine RNase Inhibitor: Oxidation-Resistant RNA Degradation Prevention details how recombinant mouse RNase inhibitor proteins provide stable RNase A inhibition under low-reducing conditions, supporting sensitive applications such as real-time RT-PCR and cDNA synthesis.
• Oxidation-Resistant RNA Protection: The Strategic Imperative emphasizes that safeguarding RNA from degradation is essential in clinical and research settings, especially when working with structured viral RNAs and advanced diagnostics.

While these articles focus on workflow integrity and the prevention of unwanted RNA degradation, the cgSHAPE-seq study uniquely addresses the targeted degradation of pathogenic RNA for therapeutic purposes. Both contexts require stringent RNA handling and integrity, but the latter leverages controlled, site-specific RNA cleavage as an antiviral strategy.

Limitations and Transferability

Although cgSHAPE-seq provides single-nucleotide resolution mapping of small molecule binding on structured RNA, its reliance on probe synthesis and specialized sequencing infrastructure may limit immediate adoption in every laboratory. Functional validation of mapped binding sites remains necessary, as RNA structure and ligand accessibility may differ in cellular versus in vitro contexts. Additionally, the transferability of the approach to other viral or cellular RNAs will depend on the availability of suitable acylating probes and chimeric recruiter designs. Nevertheless, the general strategy is adaptable and could inform the discovery of RNA-targeted therapeutics across diverse RNA viruses (reference).

Why this cross-domain matters, maturity, and limitations

The application of cgSHAPE-seq, originally developed for basic RNA structural mapping, to the rational design of antiviral RNA-degrading chimeras represents a significant advance at the intersection of RNA structural biology and therapeutic development. While the technology is at the proof-of-concept stage for SARS-CoV-2, further validation in animal models and diverse viral systems will be needed to generalize its clinical utility (reference).

Research Support Resources

For researchers aiming to replicate or extend cgSHAPE-seq workflows, meticulous RNA handling and protection from nonspecific RNase activity are essential. Utilization of an oxidation-resistant RNase A inhibitor, such as the Murine RNase Inhibitor (SKU K1046), can help prevent unintended RNA degradation during in vitro transcription, reverse transcription, and chimera screening assays (workflow_recommendation). Its improved stability in low-reducing environments supports sensitive applications in RNA structural mapping and antiviral research. For further reading on best practices in RNA protection and workflow design, see in-depth discussions in internal resource 1 and internal resource 2.